These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
219 related articles for article (PubMed ID: 16621242)
41. Supplementation of vitamin D plus calcium is effective in corticosteroid-induced osteoporosis management. Bijlsma JW Clin Exp Rheumatol; 2000; 18(1):3-4. PubMed ID: 10777337 [No Abstract] [Full Text] [Related]
42. Evidence based medicine and effective interventions of pharmacological therapy for the prevention of osteoporotic fractures. Cesareo R; Iozzino M; Alva D; Napolitano C; De Rosa B; Contini S; Mallardo L; Lauria A; Reda G; Orsini A Minerva Endocrinol; 2007 Dec; 32(4):275-95. PubMed ID: 18091664 [TBL] [Abstract][Full Text] [Related]
43. [Evidence of risedronate for treatment of osteoporosis]. Soen S Nihon Rinsho; 2007 Nov; 65 Suppl 9():344-7. PubMed ID: 18161128 [No Abstract] [Full Text] [Related]
44. Monthly risedronate (Actonel) for postmenopausal osteoporosis. Med Lett Drugs Ther; 2008 Sep; 50(1294):69-70. PubMed ID: 18772843 [No Abstract] [Full Text] [Related]
45. Calcium and vitamin D for osteoporotic fracture prevention. Carmona RJ; Adachi JD Pol Arch Med Wewn; 2007 Oct; 117(10):441-2. PubMed ID: 18320782 [No Abstract] [Full Text] [Related]
46. [New data on the pathogenesis of steroid-induced osteoporosis: consequences for therapy and prevention]. Hüfner M; Siggelkow H Dtsch Med Wochenschr; 2003 Jul; 128(30):1602-8. PubMed ID: 12884149 [No Abstract] [Full Text] [Related]
52. Antiresorption therapy and reduction in fracture susceptibility in the osteoporotic elderly patient: open study. Muscoso E; Puglisi N; Mamazza C; Lo Giudice F; Testai M; Abbate S; Santangelo A; Panebianco P; Maugeri D Eur Rev Med Pharmacol Sci; 2004; 8(2):97-102. PubMed ID: 15267123 [TBL] [Abstract][Full Text] [Related]
53. [Osteoporosis compounds in general practice. That is REAL: in routine practice the better choice]. MMW Fortschr Med; 2007 Mar; 149(13):50. PubMed ID: 17672400 [No Abstract] [Full Text] [Related]
54. [Comparative analysis of programs of complete correction osteogenic in patients with chronic pancreatitis]. Babinets' LS; Semenova IV; Borovyk IO Wiad Lek; 2014; 67(2 Pt 2):282-4. PubMed ID: 25796849 [TBL] [Abstract][Full Text] [Related]
55. Response to oral bisphosphonates in subgroups of younger and older postmenopausal women. Stovall DW; Beard MK; Barbier S; Chen E; Rosenberg E; de Papp AE J Womens Health (Larchmt); 2010 Mar; 19(3):491-7. PubMed ID: 20141367 [TBL] [Abstract][Full Text] [Related]
56. Changes in urinary NTX levels in patients with primary osteoporosis undergoing long-term bisphosphonate treatment. Iba K; Takada J; Hatakeyama N; Ozasa Y; Wada T; Yamashita T J Orthop Sci; 2008 Sep; 13(5):438-41. PubMed ID: 18843458 [TBL] [Abstract][Full Text] [Related]
57. Re "Effect of long-term treatment with risedronate on arterial compliance in osteoporotic patients with cardiovascular risk factors" by A. Luckish et al. Ye Y; Hu SJ Bone; 2009 Sep; 45(3):609-10; author reply 611. PubMed ID: 19465167 [No Abstract] [Full Text] [Related]
58. [Efficacy and tolerability of once-weekly administration of 35 mg alendronate and 17.5 mg risedronate]. Kishimoto H Nihon Rinsho; 2007 Nov; 65 Suppl 9():365-8. PubMed ID: 18161133 [No Abstract] [Full Text] [Related]
59. Are there any alternatives to alendronate (Fosamax) for osteoporosis to avoid the risk of osteonecrosis of the jaw? Wynn RL Gen Dent; 2007; 55(6):495-8. PubMed ID: 18050572 [No Abstract] [Full Text] [Related]